|
1
|
Agrawal N, Akbani R, Aksoy BA, Ally A,
Arachchi H, Asa SL, Auman JT, Balasundaram M, Balu S, Baylin SB, et
al: Integrated genomic characterization of papillary thyroid
carcinoma. Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Olaleye O, Ekrikpo U, Moorthy R, Lyne O,
Wiseberg J, Black M and Mitchell D: Increasing incidence of
differentiated thyroid cancer in South East England: 1987–2006. Eur
Arch Otorhinolaryngol. 268:899–906. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Londero SC, Krogdahl A, Bastholt L,
Overgaard J, Trolle W, Pedersen HB, Bentzen J, Schytte S,
Christiansen P and Godballe C: Papillary thyroid microcarcinoma in
Denmark 1996–2008: A national study of epidemiology and clinical
significance. Thyroid. 23:1159–1164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hay ID, Thompson GB, Grant CS, Bergstralh
EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL,
et al: Papillary thyroid carcinoma managed at the Mayo Clinic
during six decades (1940–1999): Temporal trends in initial therapy
and long-term outcome in 2444 consecutively treated patients. World
J Surg. 26:879–885. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ito Y, Miyauchi A, Kudo T, Kihara M,
Fukushima M and Miya A: The effectiveness of prophylactic modified
neck dissection for reducing the development of lymph node
recurrence of papillary thyroid carcinoma. World J Surg.
41:2283–2289. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Perkel JM: Visiting ‘Noncodarnia’.
Biotechniques. 54:303–304. 2013. View Article : Google Scholar
|
|
7
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang K, Liu F, Zhou LY, Long B, Yuan SM,
Wang Y, Liu CY, Sun T, Zhang XJ and Li PF: The long noncoding RNA
CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res.
114:1377–1388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahashi K, Yan I, Haga H and Patel T:
Long noncoding RNA in liver diseases. Hepatology. 60:744–753. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Prensner JR and Chinnaiyan AM: The
emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lan X, Zhang H, Wang Z, Dong W, Sun W,
Shao L, Zhang T and Zhang D: Genome-wide analysis of long noncoding
RNA expression profile in papillary thyroid carcinoma. Gene.
569:109–117. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zerilli M, Zito G, Martorana A, Pitrone M,
Cabibi D, Cappello F, Giordano C and Rodolico V:
BRAFV600E mutation influences hypoxia-inducible
factor-1α expression levels in papillary thyroid cancer. Mod
Pathol. 23:1052–1060. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boelaert K, Horacek J, Holder RL,
Watkinson JC, Sheppard MC and Franklyn JA: Serum thyrotropin
concentration as a novel predictor of malignancy in thyroid nodules
investigated by fine-needle aspiration. J Clin Endocrinol Metab.
91:4295–4301. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiang C, Zhang ML, Zhao QZ, Xie QP, Yan
HC, Yu X, Wang P and Wang Y: LncRNA-SLC6A9-5:2: A potent sensitizer
in 131I-resistant papillary thyroid carcinoma with
PARP-1 induction. Oncotarget. 8:22954–22967. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Lu X, Geng Z, Yang G and Shi Y:
LncRNA PTCSC3/miR-574-5p governs cell proliferation and migration
of papillary thyroid carcinoma via Wnt/β-catenin signaling. J Cell
Biochem. 118:4745–4752. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu V, Singh P, Rahimy E, Zheng H, Kuo SZ,
Kim E, Wang-Rodriguez J and Ongkeko WM: RNA-seq analysis identifies
key long non-coding RNAs connected to the pathogenesis of
alcohol-associated head and neck squamous cell carcinoma. Oncol
Lett. 12:2846–2853. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luo YH, Liang L, He RQ, Wen DY, Deng GF,
Yang H, He Y, Ma W, Cai XY, Chen JQ, et al: RNA-sequencing
investigation identifies an effective risk score generated by three
novel lncRNAs for the survival of papillary thyroid cancer
patients. Oncotarget. 8:74139–74158. 2017.PubMed/NCBI
|
|
20
|
Plachov D, Chowdhury K, Walther C, Simon
D, Guenet JL and Gruss P: Pax8, a murine paired box gene
expressed in the developing excretory system and thyroid gland.
Development. 110:643–651. 1990.PubMed/NCBI
|
|
21
|
Wolfer A and Ramaswamy S: MYC and
metastasis. Cancer Res. 71:2034–2037. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu YJ, Luo XY, Yang Y, Chen CY, Zhang ZY
and Guo X: Characterization and significance of MUC1 and c-myc
expression in elderly patients with papillary thyroid carcinoma.
Genet Mol Res. 14:15325–15330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu X, Zhao L, Park JW, Willingham MC and
Cheng SY: Synergistic signaling of KRAS and thyroid hormone
receptor β mutants promotes undifferentiated thyroid cancer through
MYC up-regulation. Neoplasia. 16:757–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Van der Wal E, Bergsma AJ, Pijnenburg JM,
Van der Ploeg AT and Pijnappel WWMP: Antisense oligonucleotides
promote exon inclusion and correct the common c.-32-13T>G
GAA splicing variant in pompe disease. Mol Ther Nucleic
Acids. 7:90–100. 2017. View Article : Google Scholar : PubMed/NCBI
|
